11.05.26 -- Earlier Decisions, Better Processes Required For Automating Autologous CAR T Manufacturing

Explore how scalable bioreactor processes improve exosome yield and recovery while maintaining critical quality attributes and supporting long-term clinical manufacturing demands.

With shifting needs and requirements in advanced therapy manufacturing, embedding infrastructure flexibility is vital. Discover how to balance these variables for long-term success.

Examine a data-driven comparison of hollow-fiber and flat-sheet TFF technologies for AAV manufacturing, covering process performance, scalability, engineering considerations, and cost.

Accurate, readable pharmaceutical labels are crucial. Walk through several considerations like printing, application tolerances, and inspection to select the right machinery for your production environment.

Producing billions of dental pulp stem cells strains static culture and complicates harvest. A closed planar perfusion approach offers another route, with scale-up lessons from one developer.

Gain insight into a comparison of TMP and permeate control strategies for viral vector TFF, highlighting impacts on flux, processing time, impurity removal, and scale-up predictability across development.

Learn how thoughtful filter selection can protect LC systems, improve protein recovery, and support reliable chromatographic results with key performance data and solvent compatibility insights.

CRISPR clinical progress relies on more than biology. Advancements in delivery systems, safety protocols, manufacturing, and regulation enable clinical translation at scale.

Selecting transfection reagents can be complex. This guide evaluates targeted applications, product parameters, and why testing beyond labeled specifications matters for success.

Explore how filter size, membrane material, flow performance, and hold-up volume influence sterility, aggregate control, product recovery, and process efficiency across cell therapy workflows.

Deriving helper virus-free stable producer cell lines from high-producer cells in suspension and serum-free media provides a dependable framework for commercial AAV biomanufacturing.

Fragmented CAR T cell manufacturing workflows drive up costs and extend timelines. This case study quantifies what consolidating manufacturing and QC through automation actually delivers.

See how nuclease format, delivery method, and DNA template design influence knockout efficiency, targeted TCR integration, cell viability, and recovery.

Understand the manufacturing challenges where rapid cell expansion often conflicts with therapeutic secretion profiles, requiring sophisticated quality control and donor selection strategies.